CDXC ChromaDex Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: CDXC

Price (delayed)

$3.79

Market cap

$285.42M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.07

Enterprise value

$261.37M

ChromaDex Corp. is a science-based integrated nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to discover, develop and create ...

Highlights
The company's EPS has surged by 71% YoY and by 22% QoQ
The company's net income has surged by 70% YoY and by 24% QoQ
CDXC's quick ratio is down by 4.8% since the previous quarter and by 2.5% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: https://chromadex.com/default.aspx
Peers: NAII SGMO EXEL

Key stats

What are the main financial stats of CDXC
Market
Shares outstanding
75.31M
Market cap
$285.42M
Enterprise value
$261.37M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
10.01
Price to sales (P/S)
3.4
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.13
Earnings
Revenue
$83.57M
EBIT
-$4.94M
EBITDA
-$3.23M
Free cash flow
$6.97M
Per share
EPS
-$0.07
Free cash flow per share
$0.09
Book value per share
$0.38
Revenue per share
$1.11
TBVPS
$0.73
Balance sheet
Total assets
$54.96M
Total liabilities
$26.51M
Debt
$3.28M
Equity
$28.46M
Working capital
$28.91M
Liquidity
Debt to equity
0.12
Current ratio
2.4
Quick ratio
1.58
Net debt/EBITDA
7.44
Margins
EBITDA margin
-3.9%
Gross margin
60.8%
Net margin
-5.9%
Operating margin
-6.7%
Efficiency
Return on assets
-9.2%
Return on equity
-17.8%
Return on invested capital
-42%
Return on capital employed
-14.4%
Return on sales
-5.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CDXC stock price

How has the ChromaDex stock price performed over time
Intraday
-4.53%
1 week
-7.33%
1 month
26.76%
1 year
166.9%
YTD
165.03%
QTD
8.91%

Financial performance

How have ChromaDex's revenue and profit performed over time
Revenue
$83.57M
Gross profit
$50.78M
Operating income
-$5.6M
Net income
-$4.94M
Gross margin
60.8%
Net margin
-5.9%
CDXC's operating margin has surged by 74% year-on-year and by 18% since the previous quarter
ChromaDex's net margin has soared by 74% YoY and by 24% from the previous quarter
The company's net income has surged by 70% YoY and by 24% QoQ
ChromaDex's operating income has surged by 70% YoY and by 19% QoQ

Growth

What is ChromaDex's growth rate over time

Valuation

What is ChromaDex stock price valuation
P/E
N/A
P/B
10.01
P/S
3.4
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.13
The company's EPS has surged by 71% YoY and by 22% QoQ
CDXC's price to book (P/B) is 144% higher than its last 4 quarters average of 4.1 and 5% higher than its 5-year quarterly average of 9.5
The equity rose by 4.2% since the previous quarter
CDXC's price to sales (P/S) is 143% higher than its last 4 quarters average of 1.4 but 19% lower than its 5-year quarterly average of 4.2
The revenue has grown by 16% YoY

Efficiency

How efficient is ChromaDex business performance
The company's return on equity has surged by 74% YoY and by 24% QoQ
The company's return on sales has surged by 74% YoY and by 28% QoQ
ChromaDex's return on assets has surged by 72% YoY and by 24% QoQ
CDXC's return on invested capital has surged by 55% year-on-year and by 14% since the previous quarter

Dividends

What is CDXC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CDXC.

Financial health

How did ChromaDex financials performed over time
The total assets is 107% more than the total liabilities
The current ratio has declined by 8% year-on-year
CDXC's quick ratio is down by 4.8% since the previous quarter and by 2.5% year-on-year
ChromaDex's debt is 88% less than its equity
ChromaDex's debt has decreased by 23% YoY and by 14% from the previous quarter
CDXC's debt to equity is down by 20% year-on-year and by 14% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.